(MedPage Today) -- The novel anticoagulant apixaban reduces the risk of stroke and major bleeding among patients with atrial fibrillation, regardless of baseline risk, a secondary analysis of the ARISTOTLE trial showed.
Squibb NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the reductions in stroke or
systemic embolism, major bleeding and mortality demonstrated with ELIQUIS®
compared to warfarin in the ARISTOTLE trial...
MUNICH (MedPage Today) -- The novel anticoagulant apixaban is better than warfarin at preventing stroke and reducing mortality independent of renal function, a secondary analysis of the ARISTOTLE trial showed.
PARIS (MedPage Today) -- The ARISTOTLE trial pitting the novel anticoagulant apixaban against warfarin for preventing stroke in patients with atrial fibrillation looks like it will be the stand-out of this year's meeting of the European Society of...
Pfizer and Bristol-Myers Squibb said today that their new oral direct Factor Xa drug apixaban, which will be marketed under the brand name of Eliquis, had met the primary endpoint of the ARISTOTLE study.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.